{"id":"NCT03480802","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-06","primaryCompletion":"2019-09-16","completion":"2020-01-17","firstPosted":"2018-03-29","resultsPosted":"2020-11-25","lastUpdate":"2022-05-05"},"enrollment":302,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"V114","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevnar 13™","otherNames":[]},{"type":"BIOLOGICAL","name":"PNEUMOVAX™23","otherNames":[]}],"arms":[{"label":"V114","type":"EXPERIMENTAL"},{"label":"Prevnar 13™","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13™ in pneumococcal vaccine-naïve adults infected with HIV and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX™23 when administered 8 weeks after receipt of either V114 or Prevnar 13™.","primaryOutcome":{"measure":"Percentage of Participants With a Solicited Injection-site Adverse Event After Vaccination 1","timeFrame":"Up to 5 days after Vaccination 1 (Up to Day 5)","effectByArm":[{"arm":"V114","deltaMin":4.6,"sd":null},{"arm":"Prevnar 13™","deltaMin":3.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":13,"countries":["United States","France","Peru","South Africa","Thailand"]},"refs":{"pmids":["34750291"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":152},"commonTop":["Injection site pain","Injection site swelling","Fatigue","Myalgia","Headache"]}}